Out of the Woods? Considerations and Follow-up for When COVID Goes Away

Out of the Woods? Considerations and Follow-up for When COVID Goes Away Posted By:
...

As we approach the 1-year mark of COVID becoming globally prominent, we are, unfortunately, also getting into the next surge of cases. At some point, this devastating virus will run its course and become less prevalent. Unfortunately, the aftereffects of COVID will last much longer. As practitioners working in all areas of medicine, we must remind ourselves of the potential long-term effects of this virus. More importantly, we must look for them.

Since the outbreak and the subsequent rollercoaster-like phases we have witnessed throughout the country, patients have been presenting with new heart ailment symptoms. Many of these patients do have a prior history of cardiovascular disease, and some may be young and otherwise healthy. Recent observations by cardiology groups worldwide are recognizing some new symptom trends presenting to their offices. We must take note of this, as these patients could present to you. Patients who have had COVID—whether asymptomatic, mild, or severe—are now showing late effects. Illnesses such as a myocardial injury can present as new heart failure, arrhythmias, venous thromboembolism, and more. Arrhythmias can occur and start a cascade of problems resulting from the infection that may have caused myocarditis, ischemia, and electrolyte imbalances. It is imperative to critically evaluate patients who present with a new complaint and consider if they may have had COVID. While we do not yet have all the long-term information on patient impact, keeping COVID in your mind long after it goes will be a necessary obligation to your patients.

References
  • Dherange P, et al. Arrhythmias and COVID-19: A review. JACC Clin Electrophysiol. 2020;6:1193-1204.
  • Driggin E, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352-2371.
  • Garot J, et al. SARS-CoV-2 fulminant myocarditis. JACC Case Rep. 2020;2:1342-1346.
  • Uriel N, et al. Myocardial injury in COVID-19 patients: The beginning or the end? J Am Coll Cardiol. 2020;76:547-549.

Share

Filed under: Infectious Diseases , Public Health , Cardiometabolic

Related
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
My Experience With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

My Experience With GLP-1 Receptor Agonists in Pati ...

When considering the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for our pat ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Dietary Sodium Restriction in Patients With Heart Failure

Dietary Sodium Restriction in Patients With Heart ...

There are about 6.2 million adults in the United States living with heart failure (HF), according to ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Bleeding Risk with Apixaban and Systemic Fluconazole Use

Bleeding Risk with Apixaban and Systemic Fluconazo ...

We, as healthcare professionals, are aware that we must check for drug interactions in our patients ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Cardiovascular Risk in Rheumatic Inflammatory Disease

Cardiovascular Risk in Rheumatic Inflammatory Dise ...

It is well documented that those with rheumatic inflammatory diseases have an increased risk of card ...

Filed under: Cardiometabolic, Rheumatology


Continue Reading
The Latest on Heart Failure: Clinical Trials Summary

The Latest on Heart Failure: Clinical Trials Summa ...

Too often, we are faced with hectic workdays that lead into hectic home lives—when we clock ou ...

Filed under: Cardiometabolic


Continue Reading